August 4, 2017
By Alex Keown, BioSpace.com Breaking News Staff
NEWARK, Delaware – QPS Holdings is planning to expand its physical footprint in Delaware and add additional jobs.
The company, which was founded in 1995 and originally known as Quest Pharmaceutical Services, will hire an additional 31 lab technicians, which will double the number of current lab techs at two of its facilities in Delaware. Both of those spaces will undergo a renovation that includes the addition of more space to accommodate the new hires, Delaware Online reported this morning. T. Ben Hsu, the chief administrative officer of QPS, told Delaware Online that the new hires and expanded spaces are “being driven by a major expansion of translational medicine, meaning biologics, throughout the pharmaceutical industry.” As a result, QPS is preparing to play a greater role and better serve its clients in those areas, Hsu said.
On its website jobs portal, QPS lists a number of open positions for its Delaware facilities, including senior research scientist, sample collector, project assistant for clinical research and senior statistical programmer.
QPS is a contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing services to hundreds of pharmaceutical and biotechnology clients worldwide, according to company information.
The expanded space includes devoted areas for immunobioanalysis and cell culture, as well as the protein mass spectrometry area, QPS said on its website. QPS announced the expansion of its translational medicine capabilities saying it will allow company to high sample volumes required for Phase III clinical drug trials.
The new space the company will add is expected to allow QPS to provide additional services to the companies it works with, particularly those pharmaceutical companies looking to bring products to market, Hsu told the publication. The company is expected to grow from 57 employees to 88 and will include additional members to its analysis team, as well as the addition of a special group focused on regulatory demands for neutralizing antibody assays.
Translational Medicine is a growing, multi-disciplinary science focused on speeding translation of experimental discoveries into effective diagnostic tools and therapies.
“For a long time, clients have known us as the boutique CRO - a high quality outfit that can stabilize difficult assays in the initial stages of clinical investigation,” John Kolman, Global Head of Translational Medicine at QPS, said in a June statement on the company website. “Now we are in a position to follow through and support Phase III, even for very large studies.”
QPS operates facilities all over the United States as well as internationally, including facilities in Austria, India, Spain, The Netherlands and Taiwan.
